文献速递心外重症与机械循环支持

全磁悬浮离心泵与轴流泵对血管性血友病因子影响的多中心前瞻性研究

Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.
PubMed 文献 · J Heart Lung Transplant · 2019-05-17

该前瞻性多中心比较队列研究纳入60例HM3泵患者与30例随机选取的HMII泵患者,主要终点为植入后90天正常化vWF HMWM比值差异。结果显示HM3组vWF HMWM比值保留优于HMII组(54.1% vs 42.4%,p<0.0001),HM3是唯一独立预测因素。

要点

  • HM3泵较HMII泵在90天时更好保留vWF HMWM结构完整性。
  • 所有vWF检测值均在正常功能范围内,两泵间无显著差异。
  • 基线vWF HMWM结构完整性下降与心衰严重程度相关。

核心结论

  • 全磁悬浮离心流HM3左心室辅助装置较HMII机械轴承轴流泵与更好的vWF HMWMs结构保留相关。

研究设计与样本

  • 前瞻性、多中心、比较队列研究,纳入60例HM3泵患者与30例随机选取的HMII泵患者。
  • HM3患者来自NCT02892955研究,HMII患者来自NCT02158403生物样本库。

主要发现

  • HM3组与HMII组分别有51例和29例可评估患者。
  • 植入后90天HM3组vWF HMWM比值保留优于HMII组(54.1% vs 42.4%,p<0.0001)。
  • 90天时所有vWF检测(抗原、活性、凝血因子VIII活性)均在正常功能范围内,两泵间无显著差异。
  • 基线vWF HMWMs结构完整性下降与INTERMACS profile评估的心衰严重程度相关。
  • 多变量建模确定HM3泵是植入后vWF HMWMs结构完整性保留的唯一独立变量。

临床怎么用

  • 对于需要左心室辅助装置的患者,HM3泵可能较HMII泵减少vWF HMWMs降解相关的血液相容性不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increased shear stress conferred upon the circulation by continuous-flow pumps is associated with hemocompatibility-related adverse events, principally bleeding within the gastrointestinal system, and linked to the degradation of high-molecular-weight multimers (HMWMs) of von Willebrand factor (vWF). We evaluated the structure and functional characteristics of vWF HMWMs in patients with the fully magnetically levitated centrifugal-flow HeartMate 3 (HM3) and the continuous axial-flow HeartMate II (HMII) pump. Findings were correlated with bleeding events. METHODS: In a prospective, multicenter, comparative cohort study, 60 patients from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 Continued Access Protocol (NCT02892955) with an HM3 pump were compared with 30 randomly selected HMII patients from the PREVENtion of HeartMate II Pump Thrombosis study (NCT02158403) biobank. The primary end point was the difference in the normalized vWF HMWM ratio (ratio of the HMWMs to the intermediate- and low-molecular-weight multimers, normalized to pooled plasma from healthy volunteers) between the HM3 and the HMII pump at 90 days after implantation. Assay tests for vWF activity, vWF antigen, vWF activity to antigen ratio, coagulation factor VIII activity, and ADAMTS13 activity were measured by using standard protocols. Differences in these markers were compared in the context of clinical characteristics and correlated with adjudicated bleeding events within the HM3 group. RESULTS: Of 51 and 29 evaluable patients in the HM3 and HMII arms, respectively, those implanted with the HM3 pump exhibited greater preservation of the vWF HMWM ratio than those with the HMII pump at 90 days after implantation (54.1% vs 42.4%, p < 0.0001). Laboratory values for all vWF assays (antigen, activity, and coagulation factor VIII activity) remained within the normal functional range with no significant differences observed between the pumps at 90 days after implantation. At baseline, there was a decrease in the structural integrity of vWF HMWMs that correlated with increasing heart failure severity as measured by the Interagency Registry for Mechanically Assisted Circulatory Support profile. Multivariable modeling identified the HM3 pump as the only independent variable that determined post-implantation preservation of the structural integrity of vWF HMWMs. CONCLUSIONS: This prospective, multicenter comparative analysis study demonstrates that the fully magnetically levitated centrifugal-flow HM3 left ventricular assist device is associated with greater preservation of the structure of vWF HMWMs than the HMII mechanical bearing axial-flow pump.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Bansal A, Uriel N, Colombo PC, et al. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. J Heart Lung Transplant. 2019. PMID: 31147187. doi:10.1016/j.healun.2019.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。